In the first list effective in 2024, public funding was provided for 19 new
molecule-indications, including:
- 8 molecule - oncology indications,
- 11 molecule - non-oncology indications,
- 10 molecule indications dedicated to rare diseases.
The reimbursement notice effective January 1, 2024 (No. 73), compared to Notice 72, contains the following changes:
- A total of 55 products or new indications were added to the l...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
